- Home
- MUR vs XENE Comparison
MUR vs XENE Comparison
Compare MUR & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUR | XENE |
|---|---|---|
| Founded | 1950 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 3.2B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MUR | XENE |
|---|---|---|
| Price | $34.01 | $59.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | $29.29 | ★ $67.25 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $2,718,823,000.00 | $311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.67 | $2,823.63 |
| P/E Ratio | $45.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.95 | $26.74 |
| 52 Week High | $36.08 | $62.91 |
Technical Indicators
Market Signals| Indicator | MUR | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 75.34 |
| Support Level | $29.81 | $37.91 |
| Resistance Level | $34.40 | N/A |
| Average True Range (ATR) | 1.39 | 2.13 |
| MACD | 0.01 | 1.93 |
| Stochastic Oscillator | 65.03 | 84.43 |
Price Performance
Historical ComparisonAbout MUR Murphy Oil Corporation
Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States. The company also generates revenue from sales of oil and natural gas production activities.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.